Dyne Therapeutics (NASDAQ:DYN) Upgraded at Lifesci Capital

Key Points

• Dyne Therapeutics has been upgraded to a "strong-buy" rating by Lifesci Capital, indicating strong confidence from analysts in the company's future performance.
• The average target price for Dyne Therapeutics shares is currently set at $34.07, with varying ratings among analysts, including four with a strong-buy and one assigned a sell rating.
• Dyne Therapeutics reported an earnings per share (EPS) of (0.97), exceeding analysts' expectations of (0.99) for the last quarter.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) was upgraded by stock analysts at Lifesci Capital to a "strong-buy" rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

A number of other brokerages have also issued reports on DYN. Chardan Capital dropped their target price on shares of Dyne Therapeutics from $50.00 to $38.00 and set a "buy" rating on the stock in a research report on Tuesday, July 29th. JPMorgan Chase & Co. dropped their price objective on shares of Dyne Therapeutics from $10.00 to $9.00 and set a "neutral" rating on the stock in a report on Tuesday, July 15th. Sanford C. Bernstein initiated coverage on shares of Dyne Therapeutics in a research report on Tuesday, June 24th. They set a "market perform" rating and a $13.00 price objective for the company. Raymond James Financial upgraded shares of Dyne Therapeutics from an "outperform" rating to a "strong-buy" rating and increased their target price for the company from $31.00 to $35.00 in a research note on Monday, August 25th. Finally, Robert W. Baird lowered their price target on Dyne Therapeutics from $46.00 to $32.00 and set an "outperform" rating on the stock in a research note on Wednesday, June 18th. Four research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $34.07.

Dyne Therapeutics Price Performance

NASDAQ DYN opened at $15.45 on Tuesday. The stock has a 50-day simple moving average of $13.01 and a 200 day simple moving average of $11.31. Dyne Therapeutics has a twelve month low of $6.36 and a twelve month high of $35.90. The stock has a market capitalization of $2.20 billion, a PE ratio of -4.00 and a beta of 1.09. The company has a debt-to-equity ratio of 0.17, a quick ratio of 16.83 and a current ratio of 16.83.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its earnings results on Monday, July 28th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.99) by $0.02. Research analysts anticipate that Dyne Therapeutics will post -3.44 EPS for the current year.

Insider Activity

In related news, CEO John Cox sold 2,640 shares of the stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $13.41, for a total transaction of $35,402.40. Following the completion of the sale, the chief executive officer directly owned 199,539 shares of the company's stock, valued at approximately $2,675,817.99. This represents a 1.31% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 20.77% of the company's stock.

Institutional Investors Weigh In On Dyne Therapeutics

Large investors have recently made changes to their positions in the stock. RA Capital Management L.P. boosted its stake in Dyne Therapeutics by 52.2% in the 1st quarter. RA Capital Management L.P. now owns 9,714,392 shares of the company's stock worth $101,613,000 after purchasing an additional 3,333,248 shares during the period. Adage Capital Partners GP L.L.C. bought a new stake in shares of Dyne Therapeutics in the second quarter valued at about $30,378,000. Braidwell LP lifted its holdings in shares of Dyne Therapeutics by 431.6% in the first quarter. Braidwell LP now owns 3,621,344 shares of the company's stock valued at $37,879,000 after purchasing an additional 2,940,162 shares in the last quarter. Armistice Capital LLC boosted its position in shares of Dyne Therapeutics by 187.0% during the first quarter. Armistice Capital LLC now owns 2,768,000 shares of the company's stock worth $28,953,000 after buying an additional 1,803,482 shares during the period. Finally, Vestal Point Capital LP bought a new position in shares of Dyne Therapeutics during the first quarter worth about $18,828,000. Institutional investors own 96.68% of the company's stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.